{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:53:44Z","timestamp":1769129624407,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":327,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["EHRE20XX0"],"award-info":[{"award-number":["EHRE20XX0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1-P01-HL164320-01"],"award-info":[{"award-number":["1-P01-HL164320-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT2TR003430-01"],"award-info":[{"award-number":["1OT2TR003430-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL108808"],"award-info":[{"award-number":["HL108808"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["EHRE20XX0"],"award-info":[{"award-number":["EHRE20XX0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1-P01-HL164320-01"],"award-info":[{"award-number":["1-P01-HL164320-01"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT2TR003430-01"],"award-info":[{"award-number":["1OT2TR003430-01"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL108808"],"award-info":[{"award-number":["HL108808"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Epidemiologic studies on patients with asthma and in vitro data suggest a protective role of type 2 (T2) inflammation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Using a large, multisite cohort, we studied clinical outcomes after SARS-CoV-2 infection in multiple asthma endotypes and examined the effects of T2-directed biologics in infected patients with asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The National COVID Cohort Collaborative Data Enclave was used to identify and stratify patients with asthma by endotype to include those with non-T2 and T2 asthma, as well as exposure to T2-directed biologic therapy. We evaluated the risk of hospitalization, invasive mechanical ventilation, and 90-day mortality by endotype and exposure to biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For this study, 402,376 patients met the inclusion criteria, of whom 138,142 (34%) were characterized as having non-T2 asthma and 264,234 (66%) as having T2 asthma, a group further divided into 104,823 (26%) atopic, 84,440 (21%) eosinophilic, and 74,971 (19%) T2-high asthmatic endotypes. Compared with patients with non-T2 asthma, those with atopic and T2-high asthma experienced decreased odds of hospitalization and 90-day mortality. Conversely, patients with eosinophilic asthma experienced higher odds of hospitalization, intubation, and 90-day mortality. Exposure to T2-directed biologic therapies did not alter outcomes after propensity score matching. In contrast, maximum eosinophil count and recent systemic corticosteroid use were directly correlated with increased odds of all outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Coronavirus disease (COVID-19) outcomes differ depending on asthma endotype, with patients with atopic asthma experiencing lower odds and those with eosinophilic asthma experiencing higher odds of deleterious outcomes. T2-directed biologic treatment did not alter these outcomes, but recent systemic corticosteroid use predisposes all patients with asthma to adverse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202405-507oc","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:57:55Z","timestamp":1730815075000},"page":"339-349","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":0,"title":["Asthma and COVID-19: Unveiling Outcome Disparities and Treatment Impact Based on Distinct Endotypes"],"prefix":"10.1093","volume":"22","author":[{"given":"Benjamin","family":"Sines","sequence":"first","affiliation":[{"name":"Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron B.","family":"Morrison","sequence":"additional","affiliation":[{"name":"Marsico Lung Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna M.","family":"Donaldson","sequence":"additional","affiliation":[{"name":"Marsico Lung Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asiyah","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Computer Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Computer Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Peden","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"Center for Environmental Medicine, Asthma and Lung Biology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0096","authenticated-orcid":false,"given":"Camille","family":"Ehre","sequence":"additional","affiliation":[{"name":"Marsico Lung Institute"},{"name":"Center for Environmental Medicine, Asthma and Lung Biology, and"},{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"2026012203114120400_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12890-022-02230-5","article-title":"Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma","volume":"22","author":"Murphy","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012203114120400_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaci.2020.06.001","article-title":"Association of asthma and its genetic predisposition with the risk of severe COVID-19","volume":"146","author":"Zhu","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203114120400_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaci.2020.04.009","article-title":"Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2","volume":"146","author":"Jackson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203114120400_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1165\/rcmb.2021-0364OC","article-title":"The type 2 asthma mediator IL-13 inhibits severe acute respiratory syndrome coronavirus 2 infection of bronchial epithelium","volume":"66","author":"Bonser","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012203114120400_bib5","doi-asserted-by":"crossref","first-page":"e2119680119","DOI":"10.1073\/pnas.2119680119","article-title":"SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13","volume":"119","author":"Morrison","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012203114120400_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaci.2023.03.021","article-title":"Type 2 inflammation reduces SARS-CoV-2 replication in the airway epithelium in allergic asthma through functional alteration of ciliated epithelial cells","volume":"152","author":"Doni Jayavelu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203114120400_bib7","first-page":"e150107","article-title":"IL-13 is a driver of COVID-19 severity","volume":"6","author":"Donlan","year":"2021","journal-title":"JCI Insight"},{"key":"2026012203114120400_bib8","doi-asserted-by":"crossref","first-page":"ofac343","DOI":"10.1093\/ofid\/ofac343","article-title":"Safety and efficacy of dupilumab for the treatment of hospitalized patients with moderate to severe coronavirus disease 2019: a phase 2a trial","volume":"9","author":"Sasson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026012203114120400_bib9","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jaip.2022.05.041","article-title":"SARS-CoV-2 infection in severe asthma patients treated with biologics","volume":"10","author":"Papaioannou","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026012203114120400_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaip.2020.09.050","article-title":"Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak","volume":"9","author":"Rial","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026012203114120400_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203114120400_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"2026012203114120400_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026012203114120400_bib14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"2026012203114120400_bib15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012203114120400_bib16","doi-asserted-by":"crossref","first-page":"2102288","DOI":"10.1183\/13993003.02288-2021","article-title":"T2-high asthma phenotypes across lifespan","volume":"60","author":"Maison","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012203114120400_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","article-title":"The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment","volume":"28","author":"Haendel","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"2026012203114120400_bib18","doi-asserted-by":"crossref","first-page":"n1098","DOI":"10.1136\/bmj.n1098","article-title":"Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study","volume":"373","author":"Daugherty","year":"2021","journal-title":"BMJ"},{"key":"2026012203114120400_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","article-title":"Risk factors for severe COVID-19 outcomes among persons aged \u226518 years who completed a primary COVID-19 vaccination series\u2014465 health care facilities, United States, December 2020\u2013October 2021","volume":"71","author":"Yek","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026012203114120400_bib20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026012203114120400_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2021.12.034","article-title":"Eosinophilia is associated with improved COVID-19 outcomes in inhaled corticosteroid-treated patients","volume":"10","author":"Zein","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026012203114120400_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/all.14972","article-title":"Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19","volume":"77","author":"Eggert","year":"2022","journal-title":"Allergy"},{"key":"2026012203114120400_bib23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/all.14551","article-title":"Atopic status protects from severe complications of COVID-19","volume":"76","author":"Scala","year":"2021","journal-title":"Allergy"},{"key":"2026012203114120400_bib24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.anai.2020.07.012","article-title":"Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019","volume":"125","author":"Keswani","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026012203114120400_bib25","doi-asserted-by":"crossref","first-page":"100508","DOI":"10.1016\/j.waojou.2021.100508","article-title":"Severity of COVID-19 in hospitalized patients with and without atopic disease","volume":"14","author":"Timberlake","year":"2021","journal-title":"World Allergy Organ J"},{"key":"2026012203114120400_bib26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026012203114120400_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.anai.2024.01.011","article-title":"Association between allergic conditions and COVID-19 susceptibility and outcomes","volume":"132","author":"Chen","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026012203114120400_bib28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2026012203114120400_bib29","doi-asserted-by":"crossref","first-page":"eabq6352","DOI":"10.1126\/sciimmunol.abq6352","article-title":"A human model of asthma exacerbation reveals transcriptional programs and cell circuits specific to allergic asthma","volume":"8","author":"Alladina","year":"2023","journal-title":"Sci Immunol"},{"key":"2026012203114120400_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2021.06.006","article-title":"COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence","volume":"148","author":"Adir","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/3\/339\/66008324\/annalsats_22_3_339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/3\/339\/66008324\/annalsats_22_3_339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:12:07Z","timestamp":1769069527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/3\/339\/8380604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202405-507oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"2024-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}